Kommentar

Schwimmer JB et al. Effect of a low free sugar diet vs. usual diet on nonalcoholic fatty liver disease in adolescent boys: A randomized clinical trial. JAMA 2019; 321: 256 – 265

• Literatur

• 1 Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol 2019; 70: 531-544
• 2 Nier A, Brandt A, Conzelmann IB. et al. Non-Alcoholic Fatty Liver Disease in Overweight Children: Role of Fructose Intake and Dietary Pattern. Nutrients 2018;
• 3 Schwarz JM, Noworolski SM, Erkin-Cakmak A. et al. Effects of Dietary Fructose Restriction on Liver Fat, De Novo Lipogenesis, and Insulin Kinetics in Children with Obesity. Gastroenterology 2017; 153: 743-752
• 4 Schwimmer JB, Ugalde-Nicalo P, Welsh JA. et al. Effect of a Low Free Sugar Diet vs. Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial. JAMA 2019; 321: 256-265
• 5 Look AHEAD Research Group. Wing RR, Bolin P, Brancati FL. et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145-154
• 6 Vilar-Gomez E, Yasells-Garcia A, Martinez-Perez Y. et al. Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention. Hepatology 2016; 63: 1875-1887
• 7 Younossi Z, Ratziu V, Loomba R. et al. Positive results from REGENERATE: a Phase 3 international, randomized, placebocontrolled study evaluating obeticholic acid treatment for NASH. Vienna: EASL; 2019: Abstract. GS-06
• 8 Ornitz DM, Itoh N. The Fibroblast Growth Factor signaling pathway. Wiley Interdiscip Rev Dev Biol 2015; 4: 215-266
• 9 Harrison SA, Rinella ME, Abdelmalek MF. et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2018; 391: 1174-1185
• 10 Sanyal A, Charles ED, Neuschwander-Tetri BA. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 2019; 392: 2705-2717
• 11 Huber Y, Pfirrmann D, Labenz C. et al. Improvement of hepatic inflammation and fibrosis independentlyof weight loss from a short, individualized, web-based exercise program in patients with NAFLD. Vienna: EASL; 2019: Abstract. SAT-349